Search Medical Condition
Please enter condition
Please choose location from dropdown

LA ROCHE-sur-YON cedex 9, France Clinical Trials

A listing of LA ROCHE-sur-YON cedex 9, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (145) clinical trials

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Screening phase: New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic plateforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing). Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions ...

Phase

0.0 miles

Learn More »

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Patient will receive either one infusion of rituximab IV and seven administrations of rituximab SC (experimental arm) or four infusions of rituximab IV (standard arm). The hypothesis is that the use of rituximab by sub cutaneous route and the scheme of administration could: optimize rituximab exposure leading to improve response ...

Phase

0.0 miles

Learn More »

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderate to severely active CD in participants who are refractory or intolerant to corticosteroids (CS), immunosuppressants (IS), or anti-tumor necrosis factors (anti-TNFs) or have ...

Phase

0.0 miles

Learn More »

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

This two-part, open-label extension and safety monitoring study will examine the safety and efficacy of continued etrolizumab treatment in patients with moderate to severely active Crohn's disease who were previously enrolled in the etrolizumab Phase III Study GA29144.

Phase

0.0 miles

Learn More »

Neoadjuvant Treatment for Advanced Rectal Carcinoma

Colorectal cancer is one of the most frequent cancers diagnosed in France. The average age of diagnosis in 2012 was 70 years old for men and 73 years for women, confirming that colorectal cancer is a disease of the elderly population. The literature concerning combined treatments of colorectal cancer in ...

Phase

0.0 miles

Learn More »

Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia

Cardiac arrest (CA) is at present a major cause of mortality as well as a cause of disability for the surviving victims. In France, every year counts as 50,000 cardiac arrests responsible for 40 000 deaths. Thus, less than 20% of patients with heart failure discharged home. Then these patients ...

Phase N/A

0.0 miles

Learn More »

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

This is a prospective, multi-regional, observational cohort study with up to 3 years of follow up per patient. During the entire observational period (from the first patient first visit to the last patient last visit), vital status will be collected every 6 months on all patients, including those who complete ...

Phase N/A

0.0 miles

Learn More »

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

This is a phase III study assessing 2 mutli-line therapeutic strategies in patients with unresectable wild-type RAS metastatic colorectal cancer. All the available treatments are being used in each strategy (oxaliplatine, irinotecan, fluoropyrimidines, bevacizumab, cetuximab or panitumumab) but in a different order: STRATEGY A: FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with ...

Phase

0.0 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Phase

0.0 miles

Learn More »

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Phase

0.0 miles

Learn More »